Latest & greatest articles for ketamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ketamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ketamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ketamine

41. Ketamine as an adjuvant to opioids for cancer pain. (PubMed)

Ketamine as an adjuvant to opioids for cancer pain. This is an update of a review first published in 2003 and updated in 2012.Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of refractory cancer pain, when opioids alone or in combination with appropriate adjuvant analgesics prove to be ineffective. Ketamine is known to have psychomimetic (including hallucinogenic), urological, and hepatic adverse effects.To (...) determine the effectiveness and adverse effects of ketamine as an adjuvant to opioids for refractory cancer pain in adults.For this update, we searched MEDLINE (OVID) to December 2016. We searched CENTRAL (CRSO), Embase (OVID) and two clinical trial registries to January 2017.The intervention considered by this review was the addition of ketamine, given by any route of administration, in any dose, to pre-existing opioid treatment given by any route and in any dose, compared with placebo or active

Full Text available with Trip Pro

2017 Cochrane

42. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. (PubMed)

Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. Delirium is a common and serious postoperative complication. Subanaesthetic ketamine is often administered intraoperatively for postoperative analgesia, and some evidence suggests that ketamine prevents delirium. The primary purpose of this trial was to assess the effectiveness of ketamine for prevention (...) of postoperative delirium in older adults.The Prevention of Delirium and Complications Associated with Surgical Treatments [PODCAST] study is a multicentre, international randomised trial that enrolled adults older than 60 years undergoing major cardiac and non-cardiac surgery under general anaesthesia. Using a computer-generated randomisation sequence we randomly assigned patients to one of three groups in blocks of 15 to receive placebo (normal saline), low-dose ketamine (0·5 mg/kg), or high dose ketamine (1

Full Text available with Trip Pro

2017 Lancet

43. Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study)

Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Ketamine showed no cognitive or other benefit when given alongside ECT, but the study recruited fewer participants than planned and moderate benefits or harms cannot be excluded. {{author}} {{($index , , , , , , , , , , , , , , , , , , , & . Ian M Anderson 1, * , Andrew

2017 NIHR HTA programme

44. Ketamine Analgesia for Acute Pain in the Emergency Department

Ketamine Analgesia for Acute Pain in the Emergency Department Emergency Medicine > Journal Club > Archive > April 2016 Toggle navigation April 2016 Ketamine Analgesia for Acute Pain in the Emergency Department Vignette It's two o'clock in the afternoon during a typical weekend TCC shift, when you get a page that a triage patient is coming to room 4. You look at the chart and see that it's a 45-year-old man who was riding his horse and got bucked off, landing on his left arm in an awkward (...) your attending about the IV lidocaine, which the patient says hasn't really helped his pain, but Dr. Cohn just shakes his head and sighs. You then ask about giving the patient low-dose ketamine for his pain, having recently listened to a podcast on the subject ( ). Dr. Cohn laughs in your face and turns his back on you. Later, he comes back and explains that while he admittedly hasn't read the literature on the subject, he isn't a big fan of replacing one addictive substance with another

2017 Washington University Emergency Medicine Journal Club

45. Low-dose Ketamine for Acute Pain in the Emergency Department

Low-dose Ketamine for Acute Pain in the Emergency Department BestBets: Low-dose Ketamine for Acute Pain in the Emergency Department Low-dose Ketamine for Acute Pain in the Emergency Department Report By: Colby Duncan MD - Senior EM Resident Search checked by Brad Riley MD - EM Faculty Institution: Grand Rapids Medical Education Research Partners/Michigan State University Date Submitted: 15th July 2016 Date Completed: 11th February 2017 Last Modified: 11th February 2017 Status: Green (complete (...) ) Three Part Question [In ED patients with acute pain who do not respond to conventional therapies], is the [low-dose ketamine better than morphine] at [safely and effectively reducing pain scores]? Clinical Scenario A man aged 25 years presents to the ED with a closed fracture of the right humeral head. He has severe pain around the shoulder and is allergic to opioids. He is given intravenous ketorolac and midazolam. Unfortunately, the patient's pain does not improve. A colleague recommends the use

2017 BestBETS

46. IM Ketamine for Prehospital Sedation of the Agitated Patient

IM Ketamine for Prehospital Sedation of the Agitated Patient Emergency Medicine > Journal Club > Archive > November 2016 Toggle navigation November 2016 IM Ketamine for Prehospital Sedation of the Agitated Patient Vignette You are working a night shift in EM-1 and have just started to catch up after signout, consisting of more than a few inebriated patients awaiting sobriety, when you hear commotion out in the hall. EMS and police are bringing in a large, screaming, Blailing, adult male patient (...) that might reduce the chances for injury of the patient and providers? How about something that is more rapid in onset than our old “5 and 2”? You remember hearing that ketamine is now being stocked on some ambulances for this purpose. When you wake up the next day after your shift you decide to look into the evidence behind prehospital ketamine for agitated patients. PICO Question Population: Adult patients with severe agitation requiring chemical sedation in the prehospital setting Intervention: IM

2017 Washington University Emergency Medicine Journal Club

47. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.

The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature. Since the discovery of antidepressants, new treatments have emerged with fewer side effects but no greater efficacy. Glycogen synthase kinase 3 β (GSK-3β), a kinase known for its activity on glycogen synthesis, has in the last few years raised growing interest in biological psychiatry. Several efficient treatments in major depression have (...) -arrestin/AKT, and with the rapid antidepressant effect of ketamine via p70S6K.Our review focuses on mechanisms whereby the GSK-3β pathway has a part in the antidepressant effect of lithium and ketamine. This article highlights the importance of translational research from cell and animal models to the clinical setting in order to develop innovative therapeutic targets.Copyright © 2016 L’Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.

2017 L'Encephale

48. Ketamine infusion for treatment-resistant bipolar depression

Ketamine infusion for treatment-resistant bipolar depression Ketamine infusion for treatment-resistant bipolar depression Ketamine infusion for treatment-resistant bipolar depression HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Ketamine infusion for treatment-resistant bipolar depression. Lansdale: HAYES, Inc. Healthcare Technology (...) Brief Publication. 2017 Authors' conclusions Health Problem: Bipolar disorder is a chronic illness characterized by alternating periods of profound depression and excessively elevated or irritable mood (mania). These episodes of extreme mood are interspersed by periods of relatively normal mood. Bipolar disorder is a severely impairing illness associated with unemployment, decreased productivity, and excess mortality. Technology Description: Ketamine therapy for bipolar disorder often involves

2017 Health Technology Assessment (HTA) Database.

49. Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder

Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation HAYES, Inc. Ketamine as primary therapy for treatment-resistant unipolar depression or posttraumatic stress disorder. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Health Problem: Treatment-resistant depression (TRD) is typically defined as depression that does not respond to at least 2 attempts at treatment of adequate duration with appropriate doses of antidepressants, but there is no official consensus definition. Posttraumatic stress disorder (PTSD) is an anxiety

2017 Health Technology Assessment (HTA) Database.

50. Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression

Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Ketamine as an adjunct (...) Description: Intravenous injection (IV) of ketamine hydrochloride as an adjunct to electroconvulsive therapy (ECT) is intended to reduce symptoms of depression more rapidly and to a greater extent than ECT alone in patients who have TRD. Controversy: Early evidence for the antidepressant effect of ketamine came from uncontrolled studies and TRD may have diverse causes and poor response rates that make it difficult to demonstrate whether or not ketamine treatment is effective. Key Questions: Does ketamine

2017 Health Technology Assessment (HTA) Database.

51. Effectiveness of ketamine as an adjuvant to opioid-based therapy in decreasing pain associated with opioid tolerance in adults undergoing orthopedic surgery: a systematic review protocol. (PubMed)

Effectiveness of ketamine as an adjuvant to opioid-based therapy in decreasing pain associated with opioid tolerance in adults undergoing orthopedic surgery: a systematic review protocol. The objective of this systematic review is to examine the best available evidence on the clinical effectiveness of ketamine as an adjuvant to opioid-based therapy versus opioid-based therapy alone in decreasing perioperative pain associated with opioid tolerance in adult patients, aged 18-70 years, undergoing (...) orthopedic surgical procedures.The following question guides the systematic review: does the administration of ketamine as an adjuvant to opioid-based therapy, compared to opioid-based therapy alone, improve perioperative pain relief in opioid-tolerant adult patients undergoing orthopedic surgical procedures?

2016 JBI database of systematic reviews and implementation reports

52. Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. (PubMed)

Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Psychiatric symptoms in individuals who use ketamine versus methamphetamine—implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study - The Lancet Go search This Journal Full Site Access provided by , S67, October 01, 2016 Powered By Mendeley Psychiatric symptoms in individuals who use ketamine versus (...) , Central South University, Hunan 410011, China National Clinical Research Center on Mental Disorders & National Technology Institute on Mental Disorders, Hunan 410011, China Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China Published: October, 2016 DOI: Abstract Background Both ketamine and methamphetamine have been used for studying the positive, negative, and cognitive symptoms, and dopaminergic and GABAergic dysfunction observed in acute schizophrenia. We aimed

2016 Lancet

53. The effect of low-dose ketamine via patient-controlled analgesic pump on morphine consumption in the postoperative period in thoracotomies: a systematic review protocol. (PubMed)

The effect of low-dose ketamine via patient-controlled analgesic pump on morphine consumption in the postoperative period in thoracotomies: a systematic review protocol. The objective of this systematic review is to determine if adding low-dose ketamine to a morphine patient-controlled analgesic pump will have an impact on the total consumption of morphine during the first 72 hours postoperative in patients over the age of 15 undergoing surgery involving thoracotomy. In addition, secondary (...) outcomes assessing the impact on pain, nausea and vomiting will be evaluated for any alteration with ketamine co-administration.

2016 JBI database of systematic reviews and implementation reports

54. Efficacy and safety of ketamine in bipolar depression: A systematic review. (PubMed)

Efficacy and safety of ketamine in bipolar depression: A systematic review. The depression is the most prevalent state throughout the life of the bipolar patient. Ketamine has been shown to be an effective and rapid treatment for depression. The objective of the present work is to perform a systematic review on the efficacy and safety of ketamine as treatment of bipolar depression, as well as its different patterns of administration. The search found 10 relevant manuscripts that met (...) the inclusion criteria: one clinical trial, 5 cohort studies, and 4 case reports. Intravenous infusion was used in 60% of the studies. According to data, ketamine seems to be an effective and safe treatment for bipolar depression, although the length of its effect is short. Adverse effects observed generally occurred at the time of infusion, and tended to completely disappear within 1-2h. Therefore, more studies are necessary to explore new patterns of administration, as well as on its safety and adverse

2016 Revista de psiquiatria y salud mental

55. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression (PubMed)

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression. This study evaluated the efficacy of twice- and thrice-weekly intravenous administration of ketamine in sustaining initial antidepressant effects in patients with treatment-resistant (...) depression.In a multicenter, double-blind study, adults (ages 18-64 years) with treatment-resistant depression were randomized to receive either intravenous ketamine (0.5 mg/kg of body weight) or intravenous placebo, administered over 40 minutes, either two or three times weekly, for up to 4 weeks. Patients who discontinued double-blind treatment after at least 2 weeks for lack of efficacy could enter an optional 2-week open-label phase to receive ketamine with the same frequency as in the double-blind

2016 EvidenceUpdates

56. Ketamine: stimulating antidepressant treatment? (PubMed)

Ketamine: stimulating antidepressant treatment? The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression (...) and Intervention Network, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Coast Capital Savings, Johnson and Johnson, Lundbeck, Lundbeck Institute, Pfizer, Servier, St. Jude Medical, Takeda University, Health Network Foundation, and Vancouver Coastal Health Research Institute. R.M. Investigator Janssen trials of esketamine; 'paid-for' ketamine clinic operated by Oxford Health NHS Foundation Trust - fees used to support the Trust. M.J.O. Consultant: Sunovion and Acadia

Full Text available with Trip Pro

2016 BJPsych open

57. Ketamine for treatment-resistant depression: recent developments and clinical applicationsEditor's Choice FREE

Ketamine for treatment-resistant depression: recent developments and clinical applicationsEditor's Choice FREE Ketamine for treatment-resistant depression: recent developments and clinical applications | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ketamine for treatment-resistant depression: recent developments and clinical applications Article Text Clinical review Ketamine for treatment-resistant depression: recent developments

2016 Evidence-Based Mental Health

58. Effectiveness of ketamine gargle in reducing postoperative sore throat in patients undergoing airway instrumentation: a systematic review. (PubMed)

Effectiveness of ketamine gargle in reducing postoperative sore throat in patients undergoing airway instrumentation: a systematic review. Postoperative sore throat is a common, minor adverse event, second to postoperative nausea and vomiting, occurring in individuals undergoing general anesthesia. Postoperative sore throat has the potential to not only diminish patient satisfaction, but also increase the need for adjunct pain therapy in the post anesthesia care unit. Many techniques (...) are utilized to reduce postoperative sore throat; however no one intervention has proven to be completely effective. The use of ketamine gargle is a novel intervention but the effectiveness of administering it prior to induction of general anesthesia is still uncertain. Therefore, further evaluation of current evidence is needed to determine the effectiveness of ketamine gargle in reducing the incidence of postoperative sore throat.The objective of this review was to determine the effectiveness of ketamine

2015 JBI database of systematic reviews and implementation reports

59. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. (PubMed)

Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. There is emerging evidence that glutamatergic system dysfunction might play an important role in the pathophysiology of bipolar depression. This review focuses on the use of glutamate receptor modulators for depression in bipolar disorder.1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder.2 (...) . To review the acceptability of ketamine and other glutamate receptor modulators in people with bipolar disorder who are experiencing acute depression symptoms.We searched the Cochrane Depression, Anxiety and Neurosis Review Group's Specialised Register (CCDANCTR, to 9 January 2015). This register includes relevant randomised controlled trials (RCTs) from: the Cochrane Library (all years), MEDLINE (1950 to date), EMBASE (1974 to date), and PsycINFO (1967 to date). We cross-checked reference lists

Full Text available with Trip Pro

2015 Cochrane

60. Ketamine and other glutamate receptor modulators for depression in adults. (PubMed)

Ketamine and other glutamate receptor modulators for depression in adults. Considering the ample evidence of involvement of the glutamate system in the pathophysiology of depression, pre-clinical and clinical studies have been conducted to assess the antidepressant efficacy of glutamate inhibition, and glutamate receptor modulators in particular. This review focuses on the use of glutamate receptor modulators in unipolar depression.To assess the effects - and review the acceptability (...) - of ketamine and other glutamate receptor modulators in comparison to placebo (or saline placebo), other pharmacologically active agents, or electroconvulsive therapy (ECT) in alleviating the acute symptoms of depression in people with unipolar major depressive disorder.We searched the Cochrane Depression, Anxiety and Neurosis Review Group's Specialised Register (CCDANCTR, to 9 January 2015). This register includes relevant randomised controlled trials (RCTs) from: the Cochrane Library (all years), MEDLINE

2015 Cochrane